Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.
Frequently asked questions
What sector does Synairgen plc (SYGGF) operate in?
Synairgen plc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Synairgen plc (SYGGF) current stock price?
As of the latest data, Synairgen plc stock price is $0.00, with a previous close of $0.00.
What is Synairgen plc (SYGGF) current market capitalization?
Synairgen plc market cap is approximately 110.27 thousand.
What is Synairgen plc (SYGGF) Earnings Per Share (EPS)?
The trailing EPS is -$0.03.
Does Synairgen plc (SYGGF) pay dividends?
No. Synairgen plc does not pay a dividend.
What is Synairgen plc (SYGGF) beta (volatility) score?
Synairgen plc has a beta of 3.968, indicating very high volatility compared to the market.